Docoh
Loading...

17 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively. Our
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet medical need. If existing or newly
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively. Our products are used
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
if we fail to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet medical need. If existing
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
operating results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
operating results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
companies, and our operating results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively. Our products
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
operating results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we believe
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet medical need. If existing or newly
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively. Our
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
results would suffer if we fail to innovate and compete effectively. Our products are used for indications where we believe that there is an unmet
10-K
2017 FY
PCSA Processa Pharmaceuticals Inc
15 Apr 18
Annual report
8:00pm
. We could face competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate
8-K/A
PCSA Processa Pharmaceuticals Inc
16 Oct 17
Entry into a Material Definitive Agreement
8:00pm
competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to innovate and compete effectively … biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to innovate and compete effectively. The biopharmaceutical
  • 1